TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9009975
Drug: Standard insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard insulin therapy (1 injection every morning)
Study: 26421957
Drug: Reduced-GSD patch
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced-GSD patch
Study: 26421957
Drug: Reduced-EE/GSD patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced-EE/GSD patch
Study: 12895218
Drug: Loxiglumide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loxiglumide (50 mg i.v.)
Study: 12895218
Drug: Hyoscine‐N‐butyl bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine‐N‐butyl bromide (20 mg i.v.)
Study: 10897370
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Ivermectin and Albendazole (400 mg)
Study: 9557072
Drug: Increased urine
Normalized name: Urin DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased urine cathepsin B activity (10.58 +/- 8.73 pmol AMC/mg creatinine/min)
Study: 9557072
Drug: Increased urine
Normalized name: Urin DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased urine collagenase activity (8.59 +/- 4.26 pmol AMC/mg creatinine/min)
Study: 9557072
Drug: Increased urine
Normalized name: Urin DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased urine excretion of fibronectin (214 +/- 335 ng/mg creatinine)
Study: 9557072
Drug: Increased urine
Normalized name: Urin DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased urine excretion of TGF-beta 1 (283.55 +/- 248.13 pg/ml)
Study: 2941573
Drug: Intravenous ketanserin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketanserin, an antagonist of S2-serotonergic receptors
Study: 26446770
Drug: Morning administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning administration of ONO-5334 150 mg
Study: 26446770
Drug: Evening administration
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Evening administration of ONO-5334 150 mg
Study: 24395109
Drug: Dual antibody
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antibody ER assay
Study: 24395109
Drug: Single antibody
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single antibody ER assay
Study: 14519486
Drug: 1% nitroprusside‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% nitroprusside‐based gel
Study: 10958816
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition (specific amino acids not detailed)
Study: 24485216
Drug: Yearly intravenous
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Yearly intravenous zoledronate (ZOL)
Study: 16386181
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) therapy
Study: 12021623
Drug: Phenytoin group
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenytoin group (n = 9 patients treated with 3‐4 mg/kg/d sodium phenytoin)
Study: 12021623
Drug: Carbamazepine group
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine group (n = 9 patients treated with 10‐20 mg/kg/d carbamazepine)
Study: 12021623
Drug: Phenobarbital group
Normalized name: Phenobarbital
DrugBank: Phenobarbital (DB01174)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital group (n = 5 patients treated with 1.5‐4.5 mg/kg/d phenobarbital)
Study: 2288512
Drug: Nitrendipine, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine, 20 mg/day
Study: 28934784
Drug: Double Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double Injection (DI) group
Study: 28934784
Drug: Single Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Injection (SI) group
Study: 9215339
Drug: Intravenous (i.v.)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (i.v.) infusion of amino acid solution (660 mOsm/L, pH 7) for 6 hours
Study: 9215339
Drug: Subcutaneous (SC)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) infusion of amino acid solution (660 mOsm/L, pH 7) for 6 hours
Study: 3038428
Drug: Hydrochlorothiazide 15
Normalized name: hydrochlorothiazide 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 15 mg tid
Study: 28464975
Drug: Full treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full treatment protocol (experimental condition)
Study: 28464975
Drug: Treatment protocol
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment protocol without systematic exposure (control)
Study: 21039358
Drug: 5.0 mg/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 mg/ml bupivacaine
Study: 21039358
Drug: 2.5 mg/ml
Normalized name: iodine 2.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg/ml bupivacaine
Study: 18495561
Drug: Pitavastatin (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin (1, 2 and 4 mg)
Study: 17121050
Drug: Salvia miltiorrhiza
Normalized name: SALVIA MILTIORRHIZA ROOT
DrugBank: Salvia miltiorrhiza root (DB14337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvia miltiorrhiza Injection (SMI)
Study: 17121050
Drug: Shengmai Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shengmai Injection (SI)
Study: 11976818
Drug: Amifostine (AMF)
Normalized name: Amifostine
DrugBank: Amifostine (DB01143)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amifostine (AMF) 300 mg/m2, given three times weekly for 3 weeks, followed by 2 weeks off therapy.
Study: 11976818
Drug: Amifostine (AMF)
Normalized name: Amifostine
DrugBank: Amifostine (DB01143)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amifostine (AMF) 400 mg/m2, given after initial treatment in group A.
Study: 11976818
Drug: Amifostine (AMF)
Normalized name: Amifostine
DrugBank: Amifostine (DB01143)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amifostine (AMF) 400 mg/m2 in group B, given three times weekly for 3 weeks, followed by 2 weeks off therapy.
Study: 11976818
Drug: Bone marrow
Normalized name: bone marrow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone marrow progenitor assay pre- and post-amifostine treatment in group A.
Study: 11976818
Drug: Clonogenic assay
Normalized name: chlorogenic acid
DrugBank: Chlorogenic Acid (DB12029)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonogenic assay in group B before AMF treatment.
Study: 11976818
Drug: Predictive power
Normalized name: guaifenesin
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Predictive power of clonogenic assays for treatment response.
Study: 1682905
Drug: Alfuzosin (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfuzosin (2.5 mg b.i.d. up to 10 mg b.i.d.)
Study: 1682905
Drug: Propranolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (40 mg b.i.d. up to 160 mg b.i.d.)
Study: 28505954
Drug: Manipulative rehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manipulative rehabilitation (8 sessions, 30 minutes each, twice weekly for 4 weeks)
Study: 23187931
Drug: Local anesthesia
Normalized name: Esters of benzoic acid for local anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthesia and intravenous sedation
Study: 21606413
Drug: Intermediate-dose cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intermediate-dose cytarabine (12 g/m²)
Study: 21606413
Drug: High-dose cytarabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cytarabine (36 g/m²)
Study: 19564837
Drug: Inactivated subunit
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated subunit vaccine
Study: 16960527
Drug: 6% carbohydrate-electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% carbohydrate-electrolyte solution (CES)
Study: 11342725
Drug: Bupivacaine (0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (0.5% 10 ml, 50 mg) injected into cannula sites before incisions and 10 ml diluted with 100 ml saline into the peritoneal cavity at completion of the procedure
Study: 9146812
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate 200 mg biweekly for 6 weeks
Study: 2890365
Drug: Vecuronium (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium (0.1 mg kg‐1) without priming dose (Group 1)
Study: 2890365
Drug: Vecuronium (0.09
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium (0.09 mg kg‐1) with priming dose of 0.015 mg kg‐1 (Group 2)
Study: 2890365
Drug: Vecuronium (0.085
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium (0.085 mg kg‐1) with priming dose of 0.02 mg kg‐1 (Group 3)
Study: 2890365
Drug: Vecuronium (0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium (0.08 mg kg‐1) with priming dose of 0.02 mg kg‐1 (Group 4)
Study: 2890365
Drug: Suxamethonium (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suxamethonium (1.5 mg kg‐1) (Group 5)
Study: 29436761
Drug: gemigliptin 50
Normalized name: gemigliptin
DrugBank: Gemigliptin (DB12412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemigliptin 50 mg qd (G2)
Study: 29436761
Drug: gemigliptin 25
Normalized name: gemigliptin
DrugBank: Gemigliptin (DB12412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemigliptin 25 mg bid to 50 mg qd (G1/G2)
Study: 29436761
Drug: sitagliptin 100
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: sitagliptin 100 mg qd to gemigliptin 50 mg qd (S/G2)
Study: 29436761
Drug: gemigliptin 50
Normalized name: gemigliptin
DrugBank: Gemigliptin (DB12412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemigliptin 50 mg qd (G2/G2)
Study: 27220310
Drug: Revascularization +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Revascularization + Best Medical Therapy (BMT)
Study: 20117319
Drug: Evidence-based guidelines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based guidelines for diagnosis and treatment of CTS
Study: 14563967
Drug: Intrathecal urokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal urokinase infusion (ITUKI therapy)
Study: 31608799
Drug: Prasugrel 5
Normalized name: prasugrel 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 5 mg od
Study: 30511291
Drug: Low-Dose Comparator
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-Dose Comparator (LDC) - a 60-min mindfulness introduction, referral to community and digital resources, and addition to a 6-month waitlist for MTPC.
Study: 26115069
Drug: Intensive lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive lipid lowering treatment with 80 mg rosuvastatin loading followed by 40 mg daily
Study: 26115069
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care group (standard statin therapy according to current guidelines)
Study: 15719746
Drug: Zhitiaokang capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zhitiaokang capsule (ZTK) for 8 weeks
Study: 15719746
Drug: Zhibituo tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zhibituo tablet (Control) for 8 weeks
Study: 8541097
Drug: Profiles of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Profiles of progesterone through the cycle obtained from daily saliva sampling
Study: 2172371
Drug: Dihydralazine at
Normalized name: dihydralazine
DrugBank: Dihydralazine (DB12945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydralazine at a dose of 4 micrograms/kg per min (Control)
Study: 2172371
Drug: Perindoprilat at
Normalized name: perindoprilat
DrugBank: Perindoprilat (DB14213)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindoprilat at a dose of 1 microgram/kg per min
Study: 2172371
Drug: Perindoprilat at
Normalized name: perindoprilat
DrugBank: Perindoprilat (DB14213)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindoprilat at a dose of 2.5 micrograms/kg per min
Study: 422029
Drug: Diane (cyproteronazetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diane (cyproteronazetate 2 mg, ethinyloestradiol 50 mcg)
Study: 422029
Drug: Neogynon (D‐Norgestrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neogynon (D‐Norgestrel 0.25 mg, ethinyloestradiol 50 mcg)
Study: 422029
Drug: Lyndiol (Lynestrenol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyndiol (Lynestrenol 2.5 mg with ethinyloestradiol 50 mcg)
Study: 26260780
Drug: Rumination-focused cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rumination-focused cognitive behaviour therapy
Study: 21936344
Drug: Tianeptine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tianeptine (3 x 12.5 mg daily)
Study: 18421047
Drug: Dexamethasone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (8 mg/m2/d)
Study: 18421047
Drug: Dexamethasone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (8 mg/m2/d) in low-risk arm
Study: 18421047
Drug: Dexamethasone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (8 mg/m2/d) in standard/high-risk arm
Study: 18421047
Drug: Dexamethasone pharmacokinetics
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone pharmacokinetics
Study: 16025957
Drug: Danning Tablet
Normalized name: chlorpheniramine tannate Oral Tablet [Ed Chlor Tan]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danning Tablet (DNT)
Study: 12660056
Drug: Stepped care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepped care (3-month multicomponent intervention led by a non-medical health worker including psychoeducational group intervention, structured follow-up, and drug treatment for severe depression)
Study: 8551753
Drug: Heparin-coated perfusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated perfusion circuits (Carmeda process; Medtronic Cardiopulmonary)
Study: 8551753
Drug: Standard systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard systemic heparin (300 U/kg)
Study: 1867303
Drug: Topical indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical indomethacin 1% suspension
Study: 1867303
Drug: Topical indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical indomethacin 1% suspension (after placebo)
Study: 7068283
Drug: Cefaclor 500
Normalized name: cefaclor 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor 500 mg administered thrice daily
Study: 7068283
Drug: Amoxycillin administered
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin administered thrice daily
Study: 30191395
Drug: Behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioural therapy with a written checklist for parents to fully complete (Group II)
Study: 30191395
Drug: Behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioural therapy as a written guideline (Group I)
Study: 30191395
Drug: Desmopressin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin treatment plus verbal behavioural therapy (Group III)
Study: 26467797
Drug: Preoperative CA19‐9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative CA19‐9 ≥300 U/ml
Study: 18555556
Drug: High-dose epirubicin/cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose epirubicin/cisplatin
Study: 17697200
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg q.d.s.
Study: 17697200
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg b.d.
Study: 17697201
Drug: Esomeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole (40 or 80 mg)
Study: 8328192
Drug: rt-PA (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: rt-PA (100 mg in 90 min)
Study: 25177814
Drug: Meldonium (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meldonium (500 mg/day) for 3 months
Study: 20350924
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine and Pioglitazone
Study: 7483804
Drug: Meningococcal group
Normalized name: meningococcal group B vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meningococcal group B (15:P1.3) outer membrane protein vaccine, two doses six weeks apart
Study: 7483804
Drug: Meningococcal group
Normalized name: meningococcal group B vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meningococcal group B (15:P1.3) outer membrane protein vaccine
Study: 7483804
Drug: Control vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control vaccine (Menomune, A, C, Y and W135 meningococcal polysaccharide vaccine)
Study: 2278224
Drug: Oral indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral indomethacin (0.2 mg/kg at 24th, 36th, and 60th hour of age)
Study: 2278224
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 ml 0.33% saline in 5% G/W solution at the same schedule)
Study: 29723441
Drug: Hydrocodone extended-release
Normalized name: hydrocodone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone extended-release (ER) 45 mg
Study: 29723441
Drug: Intranasal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal administration of finely milled hydrocodone ER, hydrocodone powder, and finely milled Zohydro® ER
Study: 25568560
Drug: Capsules containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules containing 500 mg of powdered sumac fruits, three times a day for one month
Study: 22677302
Drug: 75 mg/ml
Normalized name: urea 375 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg/ml diclofenac sodium HPβCD (i.m.)
Study: 22677302
Drug: 75 mg/ml
Normalized name: urea 375 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg/ml diclofenac sodium HPβCD (s.c.)
Study: 22677302
Drug: 25, 50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25, 50, or 75 mg/ml diclofenac sodium HPβCD (s.c.)
Study: 22677302
Drug: Voltaren® 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voltaren® 75 mg/3 ml (i.m.)
Study: 20194850
Drug: Cap 45
Normalized name: TSD HP ProTect Cap 45 mm Lblue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cap 45 (radiotherapy 45 Gy/25 fractions with concurrent capecitabine 800 mg/m² twice daily 5 days per week)
Study: 20194850
Drug: Capox 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capox 50 (radiotherapy 50 Gy/25 fractions with capecitabine 800 mg/m² twice daily 5 days per week and oxaliplatin 50 mg/m² once weekly)
Study: 18071094
Drug: Antidepressants plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants plus counseling
Study: 18071094
Drug: Treatment offered
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment offered
Study: 15900097
Drug: Low-dose FK506
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose FK506
Study: 11988250
Drug: Ibuprofen prophylaxis
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen prophylaxis for patent ductus arteriosus
Study: 7608428
Drug: Zatebradine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zatebradine (5 mg twice a day)
Study: 342622
Drug: Monovalent whole‐virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent whole‐virus vaccine (200, 400, and 800 chick cell‐agglutinating units per dose)
Study: 342622
Drug: Monovalent split‐virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent split‐virus vaccine (200, 400, and 800 chick cell‐agglutinating units per dose)
Study: 342622
Drug: Whole‐virus vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole‐virus vaccine
Study: 6459776
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide 0.125 mg
Study: 6459776
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide 0.25 mg
Study: 6459776
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide 0.5 mg
Study: 31500629
Drug: Combination containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination containing the probiotic Bifidobacterium longum BB536 and red yeast rice extract
Study: 22343090
Drug: Antidepressants (escitalopram
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants (escitalopram or amitriptyline)
Study: 7796781
Drug: AcOH (olive
Approvals — FDA: no, EMA: no, PMDA: no
Description: AcOH (olive oil plus 1 g acetic acid in the form of vinegar)
Study: 7796781
Drug: AcOH +
Approvals — FDA: no, EMA: no, PMDA: no
Description: AcOH + Bread (olive oil plus 1 g acetic acid in the form of vinegar followed by 50 g carbohydrate portions of white bread)
Study: 7796781
Drug: Blank +
Normalized name: acid black 52
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blank + Bread (olive oil without vinegar followed by 50 g carbohydrate portions of white bread)
Study: 7796781
Drug: AcNa +
Approvals — FDA: no, EMA: no, PMDA: no
Description: AcNa + Bread (olive oil plus sodium acetate followed by 50 g carbohydrate portions of white bread)
Study: 2368891
Drug: Chloral hydrate
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloral hydrate 40 mg/kg (Group 1)
Study: 2368891
Drug: Diazepam 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 0.25 mg/kg (Group 2)
Study: 2368891
Drug: Alprazolam 0.005
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam 0.005 mg/kg (both groups)
Study: 2368891
Drug: Midazolam 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.3 mg/kg (both groups)
Study: 97705
Drug: Enthusiastic messages
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enthusiastic messages of drug effects
Study: 29336900
Drug: Low-dose 99mTc-MIBI
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose 99mTc-MIBI + NC (group I)
Study: 29336900
Drug: Low-dose 99mTc-MIBI
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose 99mTc-MIBI (group II)